Gentian Diagnostics AS researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, the United States. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Gentian Diagnostics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GENT-ME's share price has been volatile over the past 3 months.
7 Day Return
NO Medical Equipment
1 Year Return
NO Medical Equipment
Return vs Industry: GENT-ME exceeded the Norwegian Medical Equipment industry which returned 9.9% over the past year.
Return vs Market: GENT-ME exceeded the Norwegian Market which returned -13.4% over the past year.
Price Volatility Vs. Market
How volatile is Gentian Diagnostics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StUpdate: Gentian Diagnostics (OB:GENT-ME) Stock Gained 44% In The Last Three Years
4 weeks ago | Simply Wall StThis Insider Has Just Sold Shares In Gentian Diagnostics AS (OB:GENT-ME)
1 month ago | Simply Wall StWe Think Gentian Diagnostics (OB:GENT-ME) Can Afford To Drive Business Growth
Is Gentian Diagnostics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GENT-ME's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GENT-ME's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GENT-ME is unprofitable, so we can't compare its PE Ratio to the XE Medical Equipment industry average.
PE vs Market: GENT-ME is unprofitable, so we can't compare its PE Ratio to the Norwegian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GENT-ME's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GENT-ME is overvalued based on its PB Ratio (5.2x) compared to the XE Medical Equipment industry average (4.4x).
How is Gentian Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Gentian Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Gentian Diagnostics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Gentian Diagnostics competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Gentian Diagnostics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GENT-ME is currently unprofitable.
Growing Profit Margin: GENT-ME is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GENT-ME is unprofitable, and losses have increased over the past 5 years at a rate of 38.1% per year.
Accelerating Growth: Unable to compare GENT-ME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GENT-ME is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-6.5%).
Return on Equity
High ROE: GENT-ME has a negative Return on Equity (-9.44%), as it is currently unprofitable.
How is Gentian Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: GENT-ME's short term assets (NOK198.2M) exceed its short term liabilities (NOK12.7M).
Long Term Liabilities: GENT-ME's short term assets (NOK198.2M) exceed its long term liabilities (NOK3.1M).
Debt to Equity History and Analysis
Debt Level: GENT-ME is debt free.
Reducing Debt: GENT-ME has no debt compared to 5 years ago when its debt to equity ratio was 5.9%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GENT-ME has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: GENT-ME has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 11.9% each year
What is Gentian Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GENT-ME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GENT-ME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GENT-ME's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GENT-ME's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GENT-ME's dividend in 3 years as they are not forecast to pay a notable one for the Norwegian market.
How experienced are the management team and are they aligned to shareholders interests?
Dr. Hilja Ibert has been the Chief Executive Officer of Gentian Diagnostics AS since July 16, 2018. Dr. Ibert has experience from the international diagnostic industry, and an extensive and strong leadersh ...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: GENT-ME insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Gentian Diagnostics AS's company bio, employee growth, exchange listings and data sources
- Name: Gentian Diagnostics AS
- Ticker: GENT-ME
- Exchange: OB
- Founded: 2001
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: kr1.047b
- Shares outstanding: 15.40m
- Website: https://www.gentian.com
Number of Employees
- Gentian Diagnostics AS
- Bjornasveien 5
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GENT-ME||OB (Oslo Bors)||Yes||Share Capital||NO||NOK||Dec 2016|
Gentian Diagnostics AS researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, the United States. It offers in-vitro diagnostic (IVD) and molecu ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/26 04:55|
|End of Day Share Price||2020/09/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.